Limited access to the profusion of sequence information derived from cancer patients worldwide stymies basic research and clinical decisions. Efforts are underway to streamline and safeguard data use.
Data collected from tens of thousands of cancer patients have been deposited in worldwide databases with the hopes that sharing information will spur development of new therapies. Despite this collaborative intent, getting access to the data can sometimes be a struggle, as David Haussler found out while trying to expand his research in cancer genomics.
''We were rejected on a certain dataset because we didn't specify [that] the work we were doing with it was strictly pediatric cancer work,'' says Haussler, who uses computational techniques to explore the molecular functions of the human genome at the University of California, Santa Cruz. ''You couldn't get the data if you weren't restricting your work to pediatric cancer.'' It's not that he lacks experience with sharing data. He's the director of the UCSC Cancer Genomics Hub, an online repository that makes available sequencing data generated by programs of the National Cancer Institute. He co-chairs a group under the umbrella of the Global Alliance for Genomics and Health (GA4GH) to standardize genomic and clinical data so that it can be easily shared among researchers. And way back in 2000, his team was the first to post publically available human genome sequences on the Internet.
Yet even Haussler sometimes runs into one of the typical problems with trying to gain access to stored data-the fact that the people collecting the data didn't take such sharing into account when they created their patient consent forms. Getting consent from subjects so that their information can be used by other researchers is only one of the challenges involved in sharing data for clinical cancer research. Data sharing requires guarantees of privacy and data security. There are also questions of whether data generated by one laboratory are comparable with those from another. And there's concern among some researchers that making their results freely available will allow others to get credit for work they haven't done. There are even questions about who should hold patient data and the practical ways of making it accessible to others.
These concerns are surfacing because many people see a lot of potential in sharing, both for advancing scientific knowledge and aiding current cancer patients. Understanding rare genetic variations that contribute to cancer requires a bigger collection of samples than any one study is likely to generate, and being able to compare rare variants can help researchers determine whether or not they're disease-causing. Widespread access to information can get patients into clinical trials faster and help inform doctors' decisions on how to treat someone. And having access to other researchers' results can both aid in validating previous studies and in generating hypotheses for new ones.
Indeed, former Vice President Joe Biden has called for increased data sharing as part of his Cancer Moonshot, an effort to double progress in the fight against cancer over the next five years. His report to the president, released in mid-October, cites ''a lack of open access and rapid sharing of research data and results allowing researchers to build on each other's successes-and failures-to make new discoveries faster,'' and calls for international standardization for truly global sharing.
In one attempt at standardization (Table 1) , the GA4GH is developing templates for consent forms. The idea is to lay out a number of categories and types of consent that will be broadly applicable to individual research projects and also allow the data to be shared with other researchers. Such templates, Haussler hopes, could make access to and analysis of datasets less complicated.
William Dalton, director of the Moffitt Cancer Center's Personalized Medicine Institute and former CEO of MCC, was thinking along those lines when he launched the Total Cancer Care project 11 years ago. When he enrolled patients, he asked for permission to follow them throughout their lifetime, collecting their clinical data, along with blood samples, tissue from their tumors, and normal tissue. The patients also granted permission to be contacted again in the future if researchers had questions or felt they could fit into a new clinical trial. That project evolved into the Oncology Research Information Exchange Network (ORIEN) that now includes 13 cancer centers.
The network has gathered data from more than 130,000 patients, all using the same standards for acquiring and sharing data and the same consent form. This, ''We've whittled down from 2,000 patients to 'here's the 144 patients that fit your trial.' Boom. Done.'' Dalton explains, allows the researchers to expand far beyond the number of samples that any one cancer center can acquire, making it easier to find rare genetic variations. The numbers required are large-a 2014 Broad Institute study published in Nature estimated that to find genes that drive cancer in 2% or more of patients, it is necessary to study approximately 100,000 tumors.
Armed with this collection of data, ORIEN researchers can search for patients who might be eligible for a clinical trial. If a pharmaceutical company approaches ORIEN researchers with their criteria for a trial, it's easy to search the database for people who match. ''We've done this,'' says Michael Caligiuri, director of the Ohio State University Comprehensive Cancer Center, who cofounded ORIEN with Dalton. ''We've whittled down from 2,000 patients to 'here's the 144 patients that fit your trial.' Boom. Done.'' That predictive ability not only makes the trials more efficient, potentially getting a new therapy to patients faster; it also helps those patients get into the trial sooner, which is particularly important for people with pancreatic or gastric cancer who might only live a few months. ''It shortened the period of assessment by weeks,'' Dalton says.
Each institution in ORIEN is responsible for taking care of its own patients' data, sharing only de-identified information with other researchers. They can, however, share it with any other researchers they'd like outside of the network, subject to a peer-reviewed application process. Pharmaceutical companies can purchase subscriptions allowing them to access the data, and ORIEN is developing a uniform contract for such subscriptions. When that's in place, Caligiuri says, it should shave a few months off the process of setting up trials.
By contrast, the focus of the American Association for Cancer Research's data sharing project is aimed not at recruiting people into clinical trials, but at aiding research. The first data release from its Genomics, Evidence, Neoplasia, Information, Exchange (GENIE) project contains clinical and genomic information from nearly 20,000 patients from eight research centers. The centers test patients for known genetic mutations for which there are existing therapies, but they also sequence many other genes that may have mutations for which currently there is no known treatment, says Charles Sawyers, chair of the human oncology and pathogenesis program at Memorial Sloan Kettering Cancer Center in New York and chair of the project's steering committee. ''We measure them because we think they're interesting, but we don't know what they are going to tell us.'' It's possible, of course, that the sharing will also help in clinical decision-making, and it might help research centers find trial participants, but GENIE itself does not have consent to re-contact patients, so unlike ORIEN, GENIE will not be able to perform follow-up analyses based on new clinical data.
An important facet of GENIE is that all member institutions have agreed to a common dictionary so that they all refer to the same conditions and measurements in the same terms to avoid, for instance, calling the same cancer by two different names. That kind of effort, ensuring that data from different sources lines up so that they can be comparedknowing, for instance, that one researcher reporting a variant is talking about the same thing as a different researcher-is critical to the success of data sharing. ''Often, people don't even report the most trivial things, like what the allele fraction was in a particular sample,'' says Louis Staudt, director of the Center for Cancer Genomics at the National Cancer Institute. For example, he says, two studies may identify a tumor as being positive for the KRAS gene, but if one has an allele frequency of 40 or 50 percent, that could mean something very different than one of only 5 or 10 percent.
Staudt is one of the leaders of the Genomic Data Commons, a $20 million NCI project at the University of Chicago designed to store and share genomic and clinical data from thousands of cancer patients. The GDC, which launched in June, already contains more than 2 petabytes of data-a petabyte is 1 million gigabytes-and should easily reach 3 PB in the coming year, Staudt says. It contains data from large NCI-funded programs such as The Cancer Genome Atlas and TARGET. In addition to making those datasets more widely available, Staudt says, ''We thought, if we made a simpleenough and useful-enough system, people could also upload their own cancer genetic data that they've gotten funded however from anywhere in the world.'' To standardize data from those disparate sources, the GDC runs them through a common set of analytic pipelines-sets of algorithms used to analyze the data-so that the data can be directly compared, and the GDC aligns them with the latest reference genome. It also requires users to label their data in a standard way. ''We do force people to put all of their clinical fields into a defined vocabulary,'' Staudt says.
Databases the size of the GDC bring logistical challenges. It would take more than three weeks to download The Cancer Genome Atlas alone. Given that, as well as concerns about which institution and which countries have possession, it's likely that the data won't be moved around in large chunks. For now, Staudt says, researchers will browse the data looking for the cancer types or genes or variants that interest them, then download only a small fraction of the entire dataset. Eventually, researchers will probably have their own analysis software, which they will send to the database to run computations on the same system that stores the data, Staudt says.
Agreeing on the significance of data can also be a challenge. Heidi Rehm, medical director of the clinical research sequencing platform at the Broad Institute in Cambridge, MA, and laboratory director of the Laboratory for Molecular Medicine at Partners Personalized Medicine, helped develop standard formats for depositing data into ClinVar, an archive that collects information about genetic variation that is clinically relevant in any disease. Whenever a researcher submits variants to ClinVar, people at the archive examine the data to make sure it follows standard nomenclature and can ''Making data available is more than just taking the data and throwing it over the wall.'' be mapped to the human genome reference sequence.
The variants in ClinVar and its sister database, ClinGen, are usually labeled by the researchers who identify them as benign or likely benign, likely to cause disease, or of unknown clinical significance. Rehm and her colleagues found that 11 percent of the nearly 120,000 unique variants in ClinGen had been interpreted by more than one laboratory, and of those, nearly 2,300 had their clinical significance interpreted differently by different labs, sometimes with one researcher labeling the variant benign while another called it pathenogenic. To deal with such disagreements, ClinVar implemented a star-rating system to label how confident researchers are of a particular variant's pathogenicity.
Some of those differences are due to what was known at the time the variant was reported. ''The standards to interpret variants a long time ago were very different,'' Rehm says. ''The literature is rife with false assertions of pathogenicity.'' Part of the solution is not to simply accept the claim about the variant, but to take the evidence gathered from individual experiments and compare it to the rest of the database. But Rehm believes that people need to accept that, even if clinicians are uncertain about the significance of a variant, they can still act on what they do know. ''It is professional opinion that guides a lot of medicine,'' she points out. ''Two different people looking at the exact same data can have a different opinion about the certainty. It's okay to have disagreements if you're all looking at the same evidence.'' Not only does the biological information from different sources have to be comparable, but the ways it's labeled for the computer have to agree as well. Mark Musen, a professor of biomedical informatics at Stanford University, runs the Center for Expanded Data Annotation and Retrieval (CEDAR), which is supported by the NIH's Big Data to Knowledge Initiative. CEDAR is building a library of templates to guide researchers through the often tedious process of creating metadata, the set of labels and descriptors that allow computers to search through a database and find, for example, all of the data relating to a particular gene or a particular type of cancer.
That sounds simple enough, but the process can be derailed by anything from typos to using different spellings for the same units-milliliter versus mL, for example. Musen says, ''It just boggles the mind that there are so many different ways of describing the same thing.'' CEDAR's goal is to provide standards and aids that avoid such confusion. ''Making data available is more than just taking the data and throwing it over the wall,'' Musen says.
While NIH guidelines require researchers to share data, journals are also encouraging the practice by requiring the data behind papers to be made available, sometimes in specific databases. Rehm, who is an editor at Cold Spring Harbor Molecular Case Studies, persuaded that journal to require that variant data be deposited in ClinVar, and she's talking to other journals about doing the same. Like many journals, MCS also requires sequencing and phenome information to be deposited in appropriate databases. In January, the International Committee of Medical Journal Editors proposed that its members require researchers to share patient data within six months of publishing a paper based on that data. That's in line with the GDC's time frame, although Staudt says in practice, the process of applying for access to the data will means it will probably be a year before others can use them. Jeffrey Drazen, editor-in-chief of the New England Journal of Medicine and a member of ICMJE, says his journal will adopt the requirement once there is a network in place for doing that sort of sharing.
Some researchers, though, have expressed resistance to sharing data, at least quickly, out of fear of what some The abundance of data sharing projects and associated groups also means an abundance of acronyms. Here are some of them decoded.
call ''research parasites''-people who profit off others' work by running analyses of their datasets and writing papers about them. In August, a group of 282 investigators calling itself the International Consortium of Investigators for Fairness in Trial Data Sharing published a commentary in NEJM calling on the ICMJE to allow exclusive use of data for at least two years. They argue that one of the incentives for researchers to participate in large, multi-center trials is the opportunity to write secondary papers based on those trials and that making the data available too quickly would put those researchers in competition with others who didn't contribute to the research, thus reducing the incentive. The requirement might also lead some people to delay publishing their first paper until they had time to write follow-up papers, the group said. Drazen agrees that there may need to be changes in the incentives that drive researchers. That's something the research community still needs to work out, he says. Staudt says that having access to shared data makes everyone's work more productive. ''No one lab can generate all the gene expression data they need to fully understand their own data,'' Staudt says. ''This kind of sharing has accelerated research, I would argue, and it's the right thing to do because the primary goal is to help people with cancer.'' Sawyers doesn't believe that generating papers from other people's data in GENIE will be much of an issue. He also thinks objections to sharing data are fading as people come to understand how much it can advance science. ''The further along we get, the less resistance there is to making it available.'' Moffitt's Dalton says it's important to keep in mind the reasons for sharing data in the first place. ''Sometimes, we lose sight and think of data sharing as the end point. That's not the end point, in my opinion,'' he says. Rather, the point is to create scientific collaborations that have the resources to advance science so that it can aid in the fight against cancer for individual patients and benefit society as a whole.
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